Interstitial Lung Disease Trial, Recruiting (NCT06626438)

Interstitial Lung Disease Trial, Recruiting NCT06626438 Sponsor: The University of Western Australia Condition: Interstitial Lung Disease

Printed from Voxsanity (voxsanity.com.au) — NCT06626438 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Interstitial Lung Disease

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You have been diagnosed with a type of lung scarring condition (called fibrotic ILD), either recently or in the past
You receive your care through the lung service at Fiona Stanley Hospital or Sir Charles Gairdner Hospital
Your lung condition was diagnosed through a specialist team meeting (a group of doctors who review cases together)
You are 18 years old or older
A doctor has confirmed your diagnosis of fibrotic ILD
Your lung scarring has been seen on a CT scan
You have any subtype of fibrotic ILD, except sarcoidosis
You are able to give your own consent to take part in the trial
You have been on a stable treatment for your lung condition for at least 1 month before the study begins

Who may not be able to join:

You have had a sudden, serious worsening of your lung condition in the 4 weeks before the study starts
It is expected that you may need a lung transplant during the study period
It is not expected that you will survive through the duration of the study (confirm with trial site)
You are currently experiencing thoughts of suicide
You are currently experiencing severe depression, active psychosis, mania, or other serious mental health conditions that need more intensive support

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 27 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Yuben Moodley, MBSS, FRACP, MD, PHD, The University of Western Australia

Phone: +61 08 6457 3333

Australian sites

Sir Charles Gairdner Hospital, Perth, Western Australia
+6147504307

Fiona Stanley Hospital, Perth, Western Australia
+61 08 6152 2222

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06626438

Sponsor: The University of Western Australia

Phase: Not Applicable

Status: Recruiting

Condition: Interstitial Lung Disease

Trial contact: +61 08 6457 3333

More information: https://clinicaltrials.gov/study/NCT06626438

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You have been diagnosed with a type of lung scarring condition (called fibrotic ILD), either recently or in the past
You receive your care through the lung service at Fiona Stanley Hospital or Sir Charles Gairdner Hospital
Your lung condition was diagnosed through a specialist team meeting (a group of doctors who review cases together)
You are 18 years old or older
A doctor has confirmed your diagnosis of fibrotic ILD
Your lung scarring has been seen on a CT scan
You have any subtype of fibrotic ILD, except sarcoidosis
You are able to give your own consent to take part in the trial
You have been on a stable treatment for your lung condition for at least 1 month before the study begins

Who may not be able to join:

You have had a sudden, serious worsening of your lung condition in the 4 weeks before the study starts
It is expected that you may need a lung transplant during the study period
It is not expected that you will survive through the duration of the study (confirm with trial site)
You are currently experiencing thoughts of suicide
You are currently experiencing severe depression, active psychosis, mania, or other serious mental health conditions that need more intensive support

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 27 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

The University of Western Australia

Registry

ClinicalTrials.gov

Start date

3 September 2025

Est. completion

1 December 2026

Where this trial is recruiting

🇦🇺 Australia

2 site(s) in Australia. Confirm current status and contact details directly with the trial site.

Primary endpoints

Health-related quality of life

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov